A Phase 1 interventional study of GSK1278863 and Placebo in Wound Healing, sponsored by GlaxoSmithKline. Completed at 7 sites in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-19.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 85 under way, 3 of them phase 3. Diabetic Foot · United States.
Among the 381 studies in Diabetic Foot with a site in United States, this one is the 155th largest by enrollment of the 322 interventional ones that give a count, is one of 20 that started in 2013, is one of 19 in phase 1, and was the 89th registered.
1,079 studies on the registry are indexed under Diabetic Foot; 222 are open to participants now.
Browse Diabetic Foot studies →66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:
Applied Biologics, LLC · Sites in United States
Ages 18+
Biodynamik, Inc · Sites in United States
Ages 22+
Lakewood-Amedex Inc · Sites in United States
Ages 18+
Capsicure, LLC · Sites in United States
Ages 18+
Reprise Biomedical, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 137 Diabetic Foot studies recruiting now, 96 (70%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
381 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 54 · Phase 3 37 · Phase 4 31
First in 1994; this study’s year is marked. 20 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is close to the median of 60 across 849 interventional studies indexed under Diabetic Foot.
Median enrollment 60 across the 322 interventional studies, 138 across the 58 observational. Of the 249 that completed or were terminated, 89 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
253 of 381 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 5 studies filed under Diabetic Foot — fewer than ten, so there is no comparison to draw.
34 of the studies in Diabetic Foot with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05369052Phase 3MicuRxSafety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI) | 2027-06-30 |
| NCT07852338Phase 3Applied Biologics, LLCa Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers | 2027-09 |
| NCT06420245Legacy Medical ConsultantsClinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management | 2026-11 |
| NCT06449638StimLabsModified Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of Hard-to-Heal DFUs | 2026-11 |
| NCT06681428Tides MedicalRising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers | 2026-11-18 |
Add all 34 to your calendar (.ics) → With an account.
Among the 381 studies in Diabetic Foot with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, placebo-controlled, single-blind (subjects and investigators will be blinded, GSK internal personnel will not be blinded), parallel-group, two part (Part A, Part B) trial in healthy volunteers and subjects with diabetic foot ulcers. Part A is designed to evaluate single applications of GSK1278863 in one cohort of healthy volunteers (intact skin) and approximately 3 cohorts of diabetic subjects. Part B is designed to evaluate first single, and then repeat applications of GSK1278863 in diabetics, both in the clinic and by subjects at home. Part B will include approximately 3 cohorts in which the concentration of drug applied will be determined by pharmacokinetic data from Part A and earlier cohorts in Part B.
Inclusion Criteria - Healthy Volunteers (Part A Cohort 1)
Inclusion Criteria - DFU Subjects must meet healthy volunteer inclusion criteria and the following
Exclusion Criteria - Healthy Volunteers (Part A Cohort 1)
Healthy volunteer exclusions apply to DFU subjects in addition to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy subjects in this arm will receive single applications of GSK1278863 or placebo (with 6:2 ratio) on intact skin in two escalating dosing periods each separated by 10 days. The first application will be with a single dose of 0.3 mg and second application will be single dose of 3 mg.
Drug: GSK1278863 · Drug: Placebo
Subjects with diabetic foot ulcer (DFU) will receive a single application of GSK1278863 or placebo (with 6:2 ratio) in two dosing periods separated by 10 days. The first application will be made on intact skin and second application directly on DFU. Dose will be based on wound area and review from previous cohort data.
Drug: GSK1278863 · Drug: Placebo
Subjects with DFU will receive single application of GSK1278863 or placebo directly on DFU. Dose will be based on wound area and review from previous cohort data.
Drug: GSK1278863 · Drug: Placebo
Subjects with DFU will receive a single application of GSK1278863 or placebo (with 6:2 ratio) in two dosing periods separated by 10 days. The first application will be made on DFU and second application on intact skin. Dose will be based on wound area and review from previous cohort data.
Drug: GSK1278863 · Drug: Placebo
Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
Drug: GSK1278863 · Drug: Placebo
Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
Drug: GSK1278863 · Drug: Placebo
Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
Drug: GSK1278863 · Drug: Placebo
White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.
White to off-white smooth ointment for topical application as single or repeat doses.
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Following Single Dose Administration (Part A)
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; other important medical events; or is associated with liver injury and impaired liver function.
Time frame: Up to a maximum of 75 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Number of Participants With AEs and SAEs Following Repeat Dose Administration (Part B)
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; other important medical events; or is associated with liver injury and impaired liver function.
Time frame: Up to a maximum of 53 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Measurement Following Single Dose Administrations (Part A)
ECG measurements were taken with the participants in supine position for at least 5 minutes. The number of participants with clinically significant abnormal ECG measurement following single dose administration for worst case post-Baseline visit has been presented.
Time frame: Up to a maximum of 75 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Number of Participants With Clinically Significant 12-lead ECG Measurement Following Repeat Dose Administrations (Part B)
ECG measurements were taken with the participants in supine position for at least 5 minutes. The number of participants with clinically significant abnormal ECG measurement following single dose administration for worst case post-Baseline visit has been presented.
Time frame: Up to a maximum of 53 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Number of Participants With Vital Sign Data Outside Clinical Concern Range Following Single Dose Administration (Part A)
Vital sign measurements included systolic blood pressure (SBP) and diastolic blood pressure (DBP). Vital signs were measured after the participants rested in a supine or semi-supine position for 5 minutes prior to the procedure. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.
Time frame: Day 1 (pre-dose and 48 hours) of Periods 1 and 2
Number of Participants With Vital Sign Data Outside Clinical Concern Range Following Repeat Dose Administration (Part B)
Vital sign measurements included systolic blood pressure (SBP) and diastolic blood pressure (DBP). Vital signs were measured after the participants rested in a supine or semi-supine position for 5 minutes prior to the procedure. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.
Time frame: Days 1 and 7 (pre-dose), Day 14 (24 hours)
Number of Participants With Abnormal Nurse/Physician Observation (Part A)
A brief physical assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen) were planned to be performed by qualified licensed, medical professional (i.e., physician, physician assistant, or nurse practitioner) but was not performed.Since data was not collected, no analysis was performed.
Time frame: Up to a maximum of 75 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Number of Participants With Abnormal Nurse/Physician Observation (Part B)
A brief physical assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen) were planned to be performed by qualified licensed, medical professional (i.e., physician, physician assistant, or nurse practitioner) but was not performed. Since data was not collected, no analysis was performed.
Time frame: Up to a maximum of 53 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Number of Participants With Hematology Values Outside the Clinical Concern Range (Part A)
Hematology parameters assessed were: platelet count, red blood cell count, white blood cell count, hemoglobin, reticulocyte count, hematocrit, absolute neutrophil count (ANC), monocytes, lymphocytes, eosinophils, basophils, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration. When a high or low value was reported, all values are presented for that time point and parameter.
Time frame: Day 1 (pre-dose)
Number of Participants With Hematology Data Outside the Clinical Concern Range (Part B)
Hematology parameters assessed were: platelet count, red blood cell count, white blood cell count, hemoglobin, reticulocyte count, hematocrit, neutrophils, monocytes, lymphocytes, eosinophils, basophils, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration. When a high or low value was reported, all values are presented for that time point and parameter.
Time frame: Day 1 (pre-dose)
Number of Participants With Clinical Chemistry Values Outside the Clinical Concern Range (Part A)
Chemistry parameters assessed were: Blood urea nitrogen (BUN), creatinine, fasting glucose, sodium, creatine phosphokinase (CPK), potassium, chloride, total carbon dioxide (CO2), calcium, glycosylated hemoglobin (HbA1C), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Gamma glutamyltransferase (GGT), Alkaline phosphatase (ALP), High sensitivity C-reactive protein (hsCRP), total and direct bilirubin, uric acid, albumin and total protein. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.
Time frame: Day 1 (pre-dose and 48 hours) in period 1; Day 1 (48 hours) in period 2
Number of Participants With Clinical Chemistry Values Outside the Clinical Concern Range (Part B)
Chemistry parameters assessed were: Blood urea nitrogen (BUN), creatinine, fasting glucose, sodium, creatine phosphokinase (CPK), potassium, chloride, total carbon dioxide (CO2), calcium, glycosylated hemoglobin (HbA1C), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Gamma glutamyltransferase (GGT), Alkaline phosphatase (ALP), High sensitivity C-reactive protein (hsCRP), total and direct bilirubin, uric acid, albumin and total protein. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.
Time frame: Days 1 and 7 (pre-dose) and Day 14 (24 hours)
Maximum Observed Concentration (Cmax) of GSK1278863 (Part A)
The pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Cmax could not be determined as data was below the limit of quantification.
Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72 hrs post-dose
Cmax of GSK1278863 (Part B)
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Cmax could not be determined as data was below the limit of quantification.
Time frame: Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14
Time of Occurrence of Cmax (Tmax) of GSK1278863 (Part A)
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tmax could not be determined as data was below the limit of quantification.
Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72hrs post-dose
Tmax of GSK1278863 (Part B)
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tmax could not be determined as data was below the limit of quantification.
Time frame: Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14
Apparent Terminal Elimination Half-life (t1/2) of GSK1278863 (Part A)
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. t1/2 could not be determined as data was below the limit of quantification.
Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72hrs post-dose
t1/2 of GSK1278863 (Part B)
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. t1/2 could not be determined as data was below the limit of quantification.
Time frame: Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14
Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) (Part A)
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tlag could not be determined as data was below the limit of quantification.
Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72hrs post-dose
Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) (Part B)
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tlag could not be determined as data was below the limit of quantification.
Time frame: Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14
Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time [AUC(0-inf)] of GSK1278863 (Part A)
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-inf) could not be determined as data was below the limit of quantification.
Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72hrs post-dose
AUC(0-inf) of GSK1278863 (Part B)
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-inf) could not be determined as data was below the limit of quantification.
Time frame: Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14
Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments [AUC(0-t)] of GSK1278863 (Part A)
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-t) could not be determined as data was below the limit of quantification.
Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72 hrs post-dose
AUC(0-t) of GSK1278863 (Part B)
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-t) could not be determined as data was below the limit of quantification.
Time frame: Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14
This was a randomized, placebo-controlled, single-blind, parallel-group, two part (Part A and Part B) study in healthy volunteers (HVT) and participants with diabetic foot ulcer (DFU).
| Milestone | Placebo HVT (Cohort 1) | Placebo DFU SD (Cohort 2, 3, 4) | A/B (Cohort 1) | C/C (Cohort 2) | D (Cohort 3) | E/E (Cohort 4) | Placebo DFU RD (Cohort 5) | R1r (Cohort 5) | Sr (Cohort 5) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 3 | 9 | 5 | 5 | 3 | 4 | 26 | 4 |
| Completed | 3 | 1 | 3 | 5 | 3 | 3 | 3 | 23 | 2 |
| Not completed | 1 | 2 | 6 | 0 | 2 | 0 | 1 | 3 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol defined stopping criteria | 1 | 1 | 3 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Investigator discretion | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrew consent | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; other important medical events; or is associated with liver injury and impaired liver function.
| Participants | Placebo HVT (Cohort 1) | A/B (Cohort 1) | Placebo DFU SD (Cohort 2, 3, 4) | C (Cohort 2) | D (Cohort 3) | E (Cohort 4) |
|---|---|---|---|---|---|---|
| AEs | 2 | 3 | 1 | 0 | 2 | 1 |
| SAEs | 0 | 0 | 0 | 0 | 0 | 1 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; other important medical events; or is associated with liver injury and impaired liver function.
| Participants | Placebo DFU RD (Cohort 5) | R1r (Cohort 5) | Sr (Cohort 5) |
|---|---|---|---|
| AEs | 2 | 5 | 2 |
| SAEs | 1 | 0 | 1 |
ECG measurements were taken with the participants in supine position for at least 5 minutes. The number of participants with clinically significant abnormal ECG measurement following single dose administration for worst case post-Baseline visit has been presented.
| Participants | Placebo HVT (Cohort 1) | Placebo DFU SD (Cohort 2, 3, 4) | A/B (Cohort 1) | C/C (Cohort 2) | D (Cohort 3) | E/E (Cohort 4) |
|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Measurement Following Single Dose Administrations (Part A) | 0 | 0 | 0 | 0 | 0 | 0 |
ECG measurements were taken with the participants in supine position for at least 5 minutes. The number of participants with clinically significant abnormal ECG measurement following single dose administration for worst case post-Baseline visit has been presented.
| Participants | Placebo DFU RD (Cohort 5) | R1r (Cohort 5) | Sr (Cohort 5) |
|---|---|---|---|
| Number of Participants With Clinically Significant 12-lead ECG Measurement Following Repeat Dose Administrations (Part B) | 0 | 0 | 0 |
Vital sign measurements included systolic blood pressure (SBP) and diastolic blood pressure (DBP). Vital signs were measured after the participants rested in a supine or semi-supine position for 5 minutes prior to the procedure. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.
| Participants | Placebo HVT (Cohort 1) | Placebo DFU SD (Cohort 2, 3, 4) | A/B (Cohort 1) | C/C (Cohort 2) | D (Cohort 3) | E/E (Cohort 4) |
|---|---|---|---|---|---|---|
| DBP Period 2; Day 1; 48 hours; Low; n=4,1,0,5,0,3 | 0 | 0 | — | 0 | — | 0 |
| DBP Period 2; Day 1; 48 hours; High; n=4,1,0,5,0,3 | 0 | 1 | — | 0 | — | 1 |
| SBP; Period 1; Day 1;pre-dose;Low;n=4,3,9,5,5,3 | 0 | 0 | 0 | 0 | 0 | 0 |
| SBP; Period 1; Day 1;pre-dose;High;n=4,3,9,5,5,3 | 0 | 0 | 0 | 2 | 1 | 0 |
| SBP; Period 1; Day 1;48 hours;Low;n=4,3,8,5,4,3 | 0 | 0 | 0 | 0 | 0 | 0 |
| SBP; Period 1; Day 1;48 hours;High;n=4,3,8,5,4,3 | 0 | 0 | 0 | 2 | 0 | 1 |
| SBP; Period 2; Day 1;pre-dose;Low;n=4,2,0,5,0,3 | 0 | 0 | — | 0 | — | 0 |
| SBP; Period 2; Day 1;pre-dose;High;n=4,2,0,5,0,3 | 0 | 0 | — | 1 | — | 0 |
| SBP; Period 2; Day 1;48 hours;Low;n=4,1,0,5,0,3 | 0 | 0 | — | 0 | — | 0 |
| SBP; Period 2; Day 1;48 hours;High;n=4,1,0,5,0,3 | 0 | 0 | — | 1 | — | 1 |
Vital sign measurements included systolic blood pressure (SBP) and diastolic blood pressure (DBP). Vital signs were measured after the participants rested in a supine or semi-supine position for 5 minutes prior to the procedure. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.
| Participants | Placebo DFU RD (Cohort 5) | R1r (Cohort 5) | Sr (Cohort 5) |
|---|---|---|---|
| DBP,Day 1,pre-dose,Low,n=4,26,4 | 0 | 0 | 0 |
| DBP,Day 1,pre-dose,High,n=4,26,4 | 0 | 1 | 0 |
| SBP,Day 1,pre-dose,Low, n=4,26,4 | 0 | 0 | 0 |
| SBP,Day 1,pre-dose,High, n=4,26,4 | 1 | 3 | 0 |
| SBP,Day 7,pre-dose,Low, n=4,25,4 | 0 | 0 | 0 |
| SBP,Day 7,pre-dose,High, n=4,25,4 | 0 | 2 | 0 |
| SBP,Day 14,24 H,Low, n=3,22,1 | 0 | 0 | 0 |
| SBP,Day 14,24 H,High, n=3,22,1 | 0 | 3 | 0 |
A brief physical assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen) were planned to be performed by qualified licensed, medical professional (i.e., physician, physician assistant, or nurse practitioner) but was not performed.Since data was not collected, no analysis was performed.
No measurements were reported for this outcome.
A brief physical assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen) were planned to be performed by qualified licensed, medical professional (i.e., physician, physician assistant, or nurse practitioner) but was not performed. Since data was not collected, no analysis was performed.
No measurements were reported for this outcome.
Hematology parameters assessed were: platelet count, red blood cell count, white blood cell count, hemoglobin, reticulocyte count, hematocrit, absolute neutrophil count (ANC), monocytes, lymphocytes, eosinophils, basophils, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration. When a high or low value was reported, all values are presented for that time point and parameter.
| Participants | Placebo HVT (Cohort 1) | Placebo DFU SD (Cohort 2, 3, 4) | A/B (Cohort 1) | C/C (Cohort 2) | D (Cohort 3) | E/E (Cohort 4) |
|---|---|---|---|---|---|---|
| Total ANC,Day 1,pre-dose,Low | 0 | 1 | 1 | 0 | 0 | 0 |
| Total ANC,Day 1,pre-dose,High | 0 | 0 | 0 | 0 | 0 | 0 |
Hematology parameters assessed were: platelet count, red blood cell count, white blood cell count, hemoglobin, reticulocyte count, hematocrit, neutrophils, monocytes, lymphocytes, eosinophils, basophils, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration. When a high or low value was reported, all values are presented for that time point and parameter.
| Participants | Placebo DFU RD (Cohort 5) | R1r (Cohort 5) | Sr (Cohort 5) |
|---|---|---|---|
| Lymphocytes, Day 1,pre-dose,Low | 0 | 1 | 0 |
| Lymphocytes, Day 1,pre-dose,High | 0 | 0 | 0 |
Chemistry parameters assessed were: Blood urea nitrogen (BUN), creatinine, fasting glucose, sodium, creatine phosphokinase (CPK), potassium, chloride, total carbon dioxide (CO2), calcium, glycosylated hemoglobin (HbA1C), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Gamma glutamyltransferase (GGT), Alkaline phosphatase (ALP), High sensitivity C-reactive protein (hsCRP), total and direct bilirubin, uric acid, albumin and total protein. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.
| Participants | Placebo HVT (Cohort 1) | Placebo DFU SD (Cohort 2, 3, 4) | A/B (Cohort 1) | C/C (Cohort 2) | D (Cohort 3) | E/E (Cohort 4) |
|---|---|---|---|---|---|---|
| Glucose,Day1,P1,pre-dose,low,n=4,3,9,5,5,3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose,Day1,P1,pre-dose,high,n=4,3,9,5,5,3 | 0 | 0 | 0 | 0 | 1 | 0 |
| Glucose,Day1,P1,48 H,low,n=4,3,8,5,4,3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose,Day1,P1,48 H,high,n=4,3,8,5,4,3 | 0 | 0 | 0 | 0 | 0 | 1 |
| Glucose,Day1,P2,48 H,low,n=4,1,0,5,0,3 | 0 | 0 | — | 0 | — | 0 |
| Glucose,Day1,P2,48 H,high,n=4,1,0,5,0,3 | 0 | 0 | — | 1 | — | 2 |
Chemistry parameters assessed were: Blood urea nitrogen (BUN), creatinine, fasting glucose, sodium, creatine phosphokinase (CPK), potassium, chloride, total carbon dioxide (CO2), calcium, glycosylated hemoglobin (HbA1C), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Gamma glutamyltransferase (GGT), Alkaline phosphatase (ALP), High sensitivity C-reactive protein (hsCRP), total and direct bilirubin, uric acid, albumin and total protein. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). When a high or low value was reported, all values are presented for that time point and parameter.
| Participants | Placebo DFU RD (Cohort 5) | R1r (Cohort 5) | Sr (Cohort 5) |
|---|---|---|---|
| Glucose,Day1,pre-dose,Low,n=4,26,4 | 0 | 0 | 0 |
| Glucose,Day1,pre-dose,High,n=4,26,4 | 0 | 5 | 1 |
| Glucose,Day7,pre-dose,Low,n=4,24,4 | 0 | 0 | 0 |
| Glucose,Day7,pre-dose,High,n=4,24,4 | 0 | 7 | 2 |
| Glucose,Day14,24H,Low,n=3,23,2 | 0 | 0 | 0 |
| Glucose,Day14,24H,High,n=3,23,2 | 2 | 9 | 0 |
The pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Cmax could not be determined as data was below the limit of quantification.
| Nanograms per milliliter (ng/mL) | A/B (Cohort 1) | C/C (Cohort 2) | D (Cohort 3) | E/E (Cohort 4) |
|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) of GSK1278863 (Part A) | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Cmax could not be determined as data was below the limit of quantification.
| ng/mL | R1r (Cohort 5) |
|---|---|
| Cmax of GSK1278863 (Part B) | NA ± NA |
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tmax could not be determined as data was below the limit of quantification.
| Hour | A/B (Cohort 1) | C/C (Cohort 2) | D (Cohort 3) | E/E (Cohort 4) |
|---|---|---|---|---|
| Time of Occurrence of Cmax (Tmax) of GSK1278863 (Part A) | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tmax could not be determined as data was below the limit of quantification.
| Hour | R1r (Cohort 5) |
|---|---|
| Tmax of GSK1278863 (Part B) | NA ± NA |
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. t1/2 could not be determined as data was below the limit of quantification.
| Hour | A/B (Cohort 1) | C/C (Cohort 2) | D (Cohort 3) | E/E (Cohort 4) |
|---|---|---|---|---|
| Apparent Terminal Elimination Half-life (t1/2) of GSK1278863 (Part A) | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. t1/2 could not be determined as data was below the limit of quantification.
| Hour | R1r (Cohort 5) |
|---|---|
| t1/2 of GSK1278863 (Part B) | NA ± NA |
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tlag could not be determined as data was below the limit of quantification.
| Hour | A/B (Cohort 1) | C/C (Cohort 2) | D (Cohort 3) | E/E (Cohort 4) |
|---|---|---|---|---|
| Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) (Part A) | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. Tlag could not be determined as data was below the limit of quantification.
| Hour | R1r (Cohort 5) |
|---|---|
| Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) (Part B) | NA ± NA |
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-inf) could not be determined as data was below the limit of quantification.
| hour*nanograms/milliliter | A/B (Cohort 1) | C/C (Cohort 2) | D (Cohort 3) | E/E (Cohort 4) |
|---|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time [AUC(0-inf)] of GSK1278863 (Part A) | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-inf) could not be determined as data was below the limit of quantification.
| hour*nanograms/milliliter | R1r (Cohort 5) |
|---|---|
| AUC(0-inf) of GSK1278863 (Part B) | NA ± NA |
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-t) could not be determined as data was below the limit of quantification.
| hour*nanograms/milliliter | A/B (Cohort 1) | C/C (Cohort 2) | D (Cohort 3) | E/E (Cohort 4) |
|---|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments [AUC(0-t)] of GSK1278863 (Part A) | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
The pharmacokinetic parameters were calculated by standard non-compartmental analysis according to current working practices and using WinNonlin Version 5.2 or higher. All calculations of non-compartmental parameters were based on actual sampling times. AUC (0-t) could not be determined as data was below the limit of quantification.
| hour*nanograms/milliliter | R1r (Cohort 5) |
|---|---|
| AUC(0-t) of GSK1278863 (Part B) | NA ± NA |
Collected over SAEs and non-serious AEs were collected from start of study treatment through the final follow-up visit each of Part A {up to a maximum of 75 days (start of study treatment through final follow up 2 [28-32 days post last dose])} and B {up to a maximum of 53 days (start of study treatment through final follow up 2 [28-32 days post last dose])}. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo HVT (Cohort 1) | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| A/B (Cohort 1) | 0/9 (0%) | 0/9 (0%) | 2/9 (22.2%) |
| Placebo DFU SD (Cohort 2, 3, 4) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| C (Cohort 2) | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| D (Cohort 3) | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| E (Cohort 4) | 0/3 (0%) | 1/3 (33.3%) | 1/3 (33.3%) |
| Placebo DFU RD (Cohort 5) | 0/4 (0%) | 1/4 (25%) | 1/4 (25%) |
| R1r (Cohort 5) | 0/26 (0%) | 0/26 (0%) | 0/26 (0%) |
| Sr (Cohort 5) | 0/4 (0%) | 1/4 (25%) | 1/4 (25%) |
| Event | Placebo HVT (Cohort 1) | A/B (Cohort 1) | Placebo DFU SD (Cohort 2, 3, 4) | C (Cohort 2) | D (Cohort 3) | E (Cohort 4) | Placebo DFU RD (Cohort 5) | R1r (Cohort 5) | Sr (Cohort 5) |
|---|---|---|---|---|---|---|---|---|---|
| OsteomyelitisInfections and infestations | 0/4 | 0/9 | 0/3 | 0/5 | 0/5 | 1/3 | 1/4 | 0/26 | 0/4 |
| Arthritis bacterialInfections and infestations | 0/4 | 0/9 | 0/3 | 0/5 | 0/5 | 0/3 | 1/4 | 0/26 | 0/4 |
| Skin ulcerSkin and subcutaneous tissue disorders | 0/4 | 0/9 | 0/3 | 0/5 | 0/5 | 0/3 | 0/4 | 0/26 | 1/4 |
| Event | Placebo HVT (Cohort 1) | A/B (Cohort 1) | Placebo DFU SD (Cohort 2, 3, 4) | C (Cohort 2) | D (Cohort 3) | E (Cohort 4) | Placebo DFU RD (Cohort 5) | R1r (Cohort 5) | Sr (Cohort 5) |
|---|---|---|---|---|---|---|---|---|---|
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/4 | 0/9 | 0/3 | 0/5 | 0/5 | 1/3 | 1/4 | 0/26 | 0/4 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/4 | 1/9 | 1/3 | 0/5 | 0/5 | 0/3 | 0/4 | 0/26 | 0/4 |
| Infected skin ulcerInfections and infestations | 0/4 | 0/9 | 0/3 | 0/5 | 0/5 | 0/3 | 1/4 | 0/26 | 1/4 |
| PruritusSkin and subcutaneous tissue disorders | 1/4 | 1/9 | 0/3 | 0/5 | 0/5 | 0/3 | 0/4 | 0/26 | 0/4 |
| Age, Continuous(Years) | Placebo HVT (Cohort 1) | Placebo DFU SD (Cohort 2, 3, 4) | A/B (Cohort 1) | C/C (Cohort 2) | D (Cohort 3) | E/E (Cohort 4) | Placebo DFU RD (Cohort 5) | R1r (Cohort 5) | Sr (Cohort 5) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 42.5 ± 14.20 | 53.0 ± 8.72 | 44.4 ± 15.27 | 52.6 ± 5.90 | 59.2 ± 7.66 | 48.3 ± 11.93 | 50.0 ± 10.42 | 55.5 ± 6.13 | 55.5 ± 5.26 | 51.2 ± 9.4 |
| Sex: Female, Male(Participants) | Placebo HVT (Cohort 1) | Placebo DFU SD (Cohort 2, 3, 4) | A/B (Cohort 1) | C/C (Cohort 2) | D (Cohort 3) | E/E (Cohort 4) | Placebo DFU RD (Cohort 5) | R1r (Cohort 5) | Sr (Cohort 5) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 3 | 0 | 0 | 0 | 1 | 3 | 1 | 9 |
| Male | 3 | 3 | 6 | 5 | 5 | 3 | 3 | 23 | 3 | 54 |
| Race/Ethnicity, Customized(Participants) | Placebo HVT (Cohort 1) | Placebo DFU SD (Cohort 2, 3, 4) | A/B (Cohort 1) | C/C (Cohort 2) | D (Cohort 3) | E/E (Cohort 4) | Placebo DFU RD (Cohort 5) | R1r (Cohort 5) | Sr (Cohort 5) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| African American/African Heritage (Her.) | 2 | 1 | 4 | 1 | 1 | 0 | 0 | 6 | 1 | 16 |
| Japanese/East Asian Her./South East Asian Her. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| White | 2 | 2 | 5 | 4 | 4 | 3 | 4 | 19 | 3 | 46 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Jun 2013 to primary completion in Feb 2017, 43 months.
Results were first posted in Aug 2019, 2 years 6 months after primary completion.
Of 26 phase 1 interventional studies under Diabetic Foot, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 43. This study's 43 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863